Cartesian Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Cartesian Therapeutics, Inc. (RNAC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.80 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $4.80, a 48.50% decline year-over-year.
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $5.25, a 62.58% decline year-over-year.
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $9.82, a 30.99% decline year-over-year.
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $9.32, a 46.44% decline year-over-year.
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $13.01, a 16.76% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $15.63, a 41.90% decline from fiscal 2023.
- Cartesian Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $26.90.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.80 10-Q · filed 2026-08-06 | $5.23 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $5.25 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $13.01 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $9.82 10-Q · filed 2025-11-06 | $13.54 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $9.32 10-Q · filed 2026-08-06 | $13.56 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $14.03 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | $15.63 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $14.23 10-Q · filed 2025-11-06 | $15.75 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $17.40 10-Q · filed 2025-08-07 | $16.05 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $15.79 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $26.90 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $26.89 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $30.51 10-Q · filed 2024-08-08 | $26.89 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $26.87 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |